The 4th annual SCAI Interface in Interventional Cardiology (SCAI i3) program took place virtually August 14-16, 2020, providing over three days and 7.5 hours of SCAI education to the interventional community in India. The program was sponsored by Sun Pharmaceuticals.

SCAI President Cindy Grines, MD, MSCAI and 25 leading U.S. and international SCAI faculty presented the latest cases on complex and calcified lesions, complications in CTO, imaging and coronary physiology, left main and coronary bifurcation, cardiogenic shock, and structural heart disease.

This program was chaired by SCAI International Committee Co-chair Ramesh Daggubati, MD, FSCAI. Participation was expected to include 1,000 interventionalists and fellows, however total participation exceeded expectations. On August 14, there were 2,095 live participants, August 15 saw 1,922 logged in, and a total of 1,696 participants on the last day of the meeting.

The program also included a special session, led by Dr. Daggubati, to celebrate the renewal of 117 Indian FSCAI members.

SCAI looks forward to continuing our partnership at the 5th annual SCAI i3 meeting in 2021, returning to Mumbai for a fully active live program.